注射用ヒトインターロイキン2の世界市場レポート 2025年

注射用ヒトインターロイキン2市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.5％で18億2,000万米ドルに成長します。予測期間中に予測される成長は、がん有病率の上昇、免疫療法治療に対する需要の増加、個別化医療の拡大、がん研究に対する政府・民間両部門からの資金提供の増加、免疫療法の利点に対する認識の高まりに関連しています。この期間の主な動向としては、バイオテクノロジーと遺伝子工学の発展、併用療法の開発、革新的なドラッグデリバリーシステム、薬剤の有効性と安全性の向上、次世代IL-2療法の開発などが挙げられます。

個別化医療の採用拡大が注射用ヒトインターロイキン2市場の拡大を牽引すると予想されます。個別化医療は、個人の遺伝子プロファイル、ライフスタイル、環境に基づいて治療や予防計画をカスタマイズするものです。個別化医療に対する需要の高まりは、遺伝子検査の進歩により、より正確な診断や、患者ごとのニーズに合わせた標的治療が可能になり、その結果、治療成績が向上し、副作用が少なくなることに後押しされています。このような個別化治療への需要の高まりは、治療効果を最適化し副作用を軽減するために、患者固有の免疫プロファイルに基づいてIL-2を投与する、個別化免疫療法レジメンにおける注射用ヒトインターロイキン2の使用を促進します。例えば、2024年2月、米国の非営利団体である個別化医療連合（Personalized Medicine Coalition）は、2023年にFDAが希少疾患患者向けに16の新規個別化医薬品を承認したと報告しました。その結果、個別化医療が重視されるようになり、注射用ヒトインターロイキン2の市場成長が促進されると予想されます。

低用量インターロイキン-2の技術革新は、注射用ヒトインターロイキン-2市場の主要プレーヤーから注目を集めており、長期的な治療選択肢の開拓に焦点が当てられています。低用量インターロイキン-2は、制御性T細胞を特異的に刺激するために少量のIL-2を投与し、炎症を抑え副作用を最小限に抑えながら免疫寛容を高めるものです。例えば、2024年10月、米国のバイオテクノロジー企業であるコヤ・セラピューティクス社は、アルツハイマー病（AD）における低用量インターロイキン-2（LD IL-2）の皮下投与の効果を調べた二重盲検試験の結果を発表しました。この試験は、Tエフェクターリンパ球に影響を与えることなく制御性T細胞（Treg）を増強し、主要および副次的エンドポイントを成功裏に達成しました。探索的データでは、低用量IL-2を4週間ごとに投与することで、認知機能が安定し、脳脊髄液（CSF）の可溶性AB42レベルが改善し、CSFのニューロフィラメント軽鎖（NfL）が安定することが明らかになりました。これらの結果は、神経変性疾患、特にアルツハイマー病の治療におけるTreg調節に対する信頼性を高めるものです。COYA301は、低用量IL-2製剤であり、皮下投与によりTregの機能を高め、炎症を調節することを目的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の注射用ヒトインターロイキン2 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の注射用ヒトインターロイキン2市場：成長率分析
• 世界の注射用ヒトインターロイキン2市場の実績：規模と成長、2019年～2024年
• 世界の注射用ヒトインターロイキン2市場の予測：規模と成長、2024年～2029年、2034年
• 世界の注射用ヒトインターロイキン2総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の注射用ヒトインターロイキン2市場：製品タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 組み換えヒトインターロイキン2
• 天然ヒトインターロイキン2
• 世界の注射用ヒトインターロイキン2市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 皮下注射
• 静脈注射
• 筋肉内注射
• 世界の注射用ヒトインターロイキン2市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 直接販売
• 薬局
• オンライン販売
• 世界の注射用ヒトインターロイキン2市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 腫瘍学
• 免疫療法
• 自己免疫疾患
• 感染症
• 世界の注射用ヒトインターロイキン2市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• クリニック
• 調査機関
• その他のエンドユーザー
• 世界の注射用ヒトインターロイキン2市場、組換えヒトインターロイキン2のサブセグメンテーション（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
• 大腸菌由来インターロイキン2
• 酵母由来インターロイキン2
• 哺乳類細胞由来インターロイキン2
• 世界の注射用ヒトインターロイキン2市場、天然ヒトインターロイキン2のサブセグメンテーション（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
• 血漿由来インターロイキン2
• 末梢血単核細胞由来インターロイキン2

第7章 地域別・国別分析

• 世界の注射用ヒトインターロイキン2市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の注射用ヒトインターロイキン2市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 注射用ヒトインターロイキン2市場：競合情勢
• 注射用ヒトインターロイキン2市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Becton Dickinson and Company（BD）Overview, Products and Services, Strategy and Financial Analysis
  • BioNTech SE Overview, Products and Services, Strategy and Financial Analysis
  • Corning Incorporated Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bio-Rad Laboratories Inc.
• StemCell Technologies Canada Inc.
• Clinigen Group
• Iovance Biotherapeutics Inc.
• CUSABIO Technology LLC
• Elabscience Biotechnology Inc.
• Enzo Biochem Inc.
• InvivoGen
• Synthekine Inc.
• BPS Bioscience Inc.
• Xilio Therapeutics Inc.
• Qkine Ltd.
• MinneBio LLC
• Akron Biotechnology LLC
• Shandong Quangang Pharmaceutical Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 注射用ヒトインターロイキン2市場2029年：新たな機会を提供する国
• 注射用ヒトインターロイキン2市場2029年：新たな機会を提供するセグメント
• 注射用ヒトインターロイキン2市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Injection human interleukin 2 is a biologic drug primarily used in immunotherapy to stimulate the growth and activity of immune cells, such as T-cells and natural killer (NK) cells. It is a recombinant form of the naturally occurring cytokine interleukin-2, which plays a crucial role in regulating immune responses. By boosting the body's immune defenses, IL-2 injection helps to recognize and target cancer cells more effectively.

The primary product types of injection human interleukin 2 are recombinant human interleukin 2 and natural human interleukin 2. Recombinant human interleukin 2 is a synthetic version produced through recombinant DNA technology. It can be administered via subcutaneous, intravenous, or intramuscular injection and is distributed through direct sales, pharmacies, and online platforms. This drug is primarily used in oncology, immunotherapy, and for treating autoimmune diseases by various end-users, including hospitals, clinics, research institutes, and more.

The injection human interleukin 2 market research report is one of a series of new reports from The Business Research Company that provides injection human interleukin 2 market statistics, including injection human interleukin 2 industry global market size, regional shares, competitors with an injection human interleukin 2 market share, detailed injection human interleukin 2 market segments, market trends and opportunities, and any further data you may need to thrive in the injection human interleukin 2 industry. This injection human interleukin 2 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The injection human interleukin 2 market size has grown rapidly in recent years. It will grow from $1.10 billion in 2024 to $1.22 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth observed in the historical period can be credited to advancements in healthcare infrastructure, a higher utilization of IL-2 for autoimmune diseases, a rising number of clinical trials, an expanding pipeline of cancer immunotherapy drugs, a growing global population, and an aging demographic.

The injection human interleukin 2 market size is expected to see rapid growth in the next few years. It will grow to $1.82 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth projected for the forecast period can be linked to the rising prevalence of cancer, increased demand for immunotherapy treatments, the expansion of personalized medicine, greater funding from both government and private sectors for cancer research, and growing awareness of the benefits of immunotherapy. Key trends during this period include advancements in biotechnology and genetic engineering, the development of combination therapies, innovative drug delivery systems, improvements in drug efficacy and safety, and the development of next-generation IL-2 therapies.

The growing adoption of personalized medicine is expected to drive the expansion of the injection human interleukin 2 market. Personalized medicine customizes treatment and prevention plans based on an individual's genetic profile, lifestyle, and environment. The rising demand for personalized medicine is fueled by advances in genetic testing, which allow for more accurate diagnoses and targeted therapies that are tailored to each patient's specific needs, resulting in better outcomes and fewer side effects. This increased demand for personalized treatments enhances the use of Injection Human Interleukin 2 in customized immunotherapy regimens, where IL-2 is administered based on the patient's unique immune profile to optimize therapeutic efficacy and reduce adverse effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the FDA approved 16 novel personalized medicines for patients with rare diseases in 2023, up from six in 2022. As a result, the growing emphasis on personalized medicine is expected to drive the market growth of injection human interleukin 2.

Innovations in low-dose interleukin-2 are gaining attention from key players in the injection human interleukin-2 market, with a focus on developing long-term treatment options. Low-dose interleukin-2 involves administering small amounts of IL-2 to specifically stimulate regulatory T cells, boosting immune tolerance while reducing inflammation and minimizing side effects. For example, in October 2024, Coya Therapeutics Inc., a U.S.-based biotech company, shared results from a double-blind study investigating the effects of subcutaneous low-dose interleukin-2 (LD IL-2) in Alzheimer's disease (AD). The study successfully met its primary and secondary endpoints, enhancing regulatory T cells (Tregs) without impacting T effector lymphocytes. Exploratory data revealed that administering low-dose IL-2 every four weeks stabilized cognition, improved cerebrospinal fluid (CSF) soluble AB42 levels, and stabilized CSF Neurofilament Light Chain (NfL). These results bolster confidence in Treg modulation for treating neurodegenerative diseases, particularly Alzheimer's. COYA 301, an investigational low-dose IL-2, seeks to enhance Treg function through subcutaneous administration for modulating inflammation.

In September 2022, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired Good Therapeutics Inc. for $250 million. This acquisition is part of Roche's strategy to enhance its immuno-oncology pipeline by developing innovative, conditionally active Interleukin-2 treatments that selectively activate immune responses within tumors, while minimizing systemic side effects. Good Therapeutics Inc. is a US-based biotech firm, focusing on creating conditionally active interleukin-2 therapies targeting programmed cell death protein 1 for cancer immunotherapy.

Major players in the injection human interleukin 2 market are F. Hoffmann-La Roche AG, Novartis AG, Becton Dickinson and Company (BD), BioNTech SE, Corning Incorporated, Bio-Rad Laboratories Inc., StemCell Technologies Canada Inc., Clinigen Group, Iovance Biotherapeutics Inc., CUSABIO Technology LLC, Elabscience Biotechnology Inc., Enzo Biochem Inc., InvivoGen, Synthekine Inc., BPS Bioscience Inc., Xilio Therapeutics Inc., Qkine Ltd., MinneBio LLC, Akron Biotechnology LLC, Shandong Quangang Pharmaceutical Co. Ltd., and Novoprotein Scientific Inc.

North America was the largest region in the injection human interleukin 2 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in injection human interleukin 2 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Injection Human Interleukin 2 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The injection human interleukin 2 market consists of sales of monoclonal antibodies, checkpoint inhibitors, cancer vaccines and immune modulators. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Injection Human Interleukin 2 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on injection human interleukin 2 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for injection human interleukin 2 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The injection human interleukin 2 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Recombinant Human Interleukin 2; Natural Human Interleukin 2
• 2) By Route Of Administration: Subcutaneous Injection; Intravenous Injection; Intramuscular Injection
• 3) By Distribution Channel: Direct Sales; Pharmacies; Online Sales
• 4) By Application: Oncology; Immunotherapy; Autoimmune Diseases
• 5) By End-User: Hospitals; Clinics; Research Institutes; Others End-Users
• Subsegments:
• 1) By Recombinant Human Interleukin 2: Escherichia Coli Derived Interleukin 2; Yeast Derived Interleukin 2; Mammalian Cell Derived Interleukin 2
• 2) By Natural Human Interleukin 2: Plasma Derived Interleukin 2; Peripheral Blood Mononuclear Cell Derived Interleukin 2
• Companies Mentioned: F. Hoffmann-La Roche AG; Novartis AG; Becton Dickinson and Company (BD); BioNTech SE; Corning Incorporated
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Injection Human Interleukin 2 Market Characteristics

3. Injection Human Interleukin 2 Market Trends And Strategies

4. Injection Human Interleukin 2 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Injection Human Interleukin 2 Growth Analysis And Strategic Analysis Framework

• 5.1. Global Injection Human Interleukin 2 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Injection Human Interleukin 2 Market Growth Rate Analysis
• 5.4. Global Injection Human Interleukin 2 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Injection Human Interleukin 2 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Injection Human Interleukin 2 Total Addressable Market (TAM)

6. Injection Human Interleukin 2 Market Segmentation

• 6.1. Global Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Human Interleukin 2
• Natural Human Interleukin 2
• 6.2. Global Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous Injection
• Intravenous Injection
• Intramuscular Injection
• 6.3. Global Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Sales
• Pharmacies
• Online Sales
• 6.4. Global Injection Human Interleukin 2 Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Immunotherapy
• Autoimmune Diseases
• Infectious Diseases
• 6.5. Global Injection Human Interleukin 2 Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Research Institutes
• Others End-Users
• 6.6. Global Injection Human Interleukin 2 Market, Sub-Segmentation Of Recombinant Human Interleukin 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Escherichia Coli Derived Interleukin 2
• Yeast Derived Interleukin 2
• Mammalian Cell Derived Interleukin 2
• 6.7. Global Injection Human Interleukin 2 Market, Sub-Segmentation Of Natural Human Interleukin 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasma Derived Interleukin 2
• Peripheral Blood Mononuclear Cell Derived Interleukin 2

7. Injection Human Interleukin 2 Market Regional And Country Analysis

• 7.1. Global Injection Human Interleukin 2 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Injection Human Interleukin 2 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Injection Human Interleukin 2 Market

• 8.1. Asia-Pacific Injection Human Interleukin 2 Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Injection Human Interleukin 2 Market

• 9.1. China Injection Human Interleukin 2 Market Overview
• 9.2. China Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Injection Human Interleukin 2 Market

• 10.1. India Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Injection Human Interleukin 2 Market

• 11.1. Japan Injection Human Interleukin 2 Market Overview
• 11.2. Japan Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Injection Human Interleukin 2 Market

• 12.1. Australia Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Injection Human Interleukin 2 Market

• 13.1. Indonesia Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Injection Human Interleukin 2 Market

• 14.1. South Korea Injection Human Interleukin 2 Market Overview
• 14.2. South Korea Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Injection Human Interleukin 2 Market

• 15.1. Western Europe Injection Human Interleukin 2 Market Overview
• 15.2. Western Europe Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Injection Human Interleukin 2 Market

• 16.1. UK Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Injection Human Interleukin 2 Market

• 17.1. Germany Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Injection Human Interleukin 2 Market

• 18.1. France Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Injection Human Interleukin 2 Market

• 19.1. Italy Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Injection Human Interleukin 2 Market

• 20.1. Spain Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Injection Human Interleukin 2 Market

• 21.1. Eastern Europe Injection Human Interleukin 2 Market Overview
• 21.2. Eastern Europe Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Injection Human Interleukin 2 Market

• 22.1. Russia Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Injection Human Interleukin 2 Market

• 23.1. North America Injection Human Interleukin 2 Market Overview
• 23.2. North America Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Injection Human Interleukin 2 Market

• 24.1. USA Injection Human Interleukin 2 Market Overview
• 24.2. USA Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Injection Human Interleukin 2 Market

• 25.1. Canada Injection Human Interleukin 2 Market Overview
• 25.2. Canada Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Injection Human Interleukin 2 Market

• 26.1. South America Injection Human Interleukin 2 Market Overview
• 26.2. South America Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Injection Human Interleukin 2 Market

• 27.1. Brazil Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Injection Human Interleukin 2 Market

• 28.1. Middle East Injection Human Interleukin 2 Market Overview
• 28.2. Middle East Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Injection Human Interleukin 2 Market

• 29.1. Africa Injection Human Interleukin 2 Market Overview
• 29.2. Africa Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Injection Human Interleukin 2 Market Competitive Landscape And Company Profiles

• 30.1. Injection Human Interleukin 2 Market Competitive Landscape
• 30.2. Injection Human Interleukin 2 Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Becton Dickinson and Company (BD) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. BioNTech SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Corning Incorporated Overview, Products and Services, Strategy and Financial Analysis

31. Injection Human Interleukin 2 Market Other Major And Innovative Companies

• 31.1. Bio-Rad Laboratories Inc.
• 31.2. StemCell Technologies Canada Inc.
• 31.3. Clinigen Group
• 31.4. Iovance Biotherapeutics Inc.
• 31.5. CUSABIO Technology LLC
• 31.6. Elabscience Biotechnology Inc.
• 31.7. Enzo Biochem Inc.
• 31.8. InvivoGen
• 31.9. Synthekine Inc.
• 31.10. BPS Bioscience Inc.
• 31.11. Xilio Therapeutics Inc.
• 31.12. Qkine Ltd.
• 31.13. MinneBio LLC
• 31.14. Akron Biotechnology LLC
• 31.15. Shandong Quangang Pharmaceutical Co. Ltd.

32. Global Injection Human Interleukin 2 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Injection Human Interleukin 2 Market

34. Recent Developments In The Injection Human Interleukin 2 Market

35. Injection Human Interleukin 2 Market High Potential Countries, Segments and Strategies

• 35.1 Injection Human Interleukin 2 Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Injection Human Interleukin 2 Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Injection Human Interleukin 2 Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer